Source: Breathe, 15 (4) 296; 10.1183/20734735.0258-2019
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Andrew W. Creamer, Alice E. Kent, Maha Albur. Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy. Breathe, 15 (4) 296; 10.1183/20734735.0258-2019

Member's Comments

No comment yet.

Related content which might interest you: “Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy” Breathe 2019; 15: 296–304. Source: Breathe, 15 (4) e152; 10.1183/20734735.5258-2019 Year: 2019 Sputum induction for assessment of biomarkers in early development of new drugs for respiratory disease in a proof of concept setting Source: International Congress 2016 – Airway biomarkers Year: 2016 Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations? Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019 Year: 2019 Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis Source: Eur Respir Rev 2017; 26: 160073 Year: 2017 Procalcitonin as a diagnostic tool in systemic bacterial sepsis Source: Annual Congress 2009 - Severe sepsis and multiple organ failure Year: 2009 Changes in empirical initial antibiotic therapy in community-acquired pneumonia: assessment of clinical failure versus discordant therapy Source: Eur Respir J 2006; 28: Suppl. 50, 736s Year: 2006 Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection Source: Eur Respir J 2010; 36: 601-607 Year: 2010 Indication for antibiotic therapy in AECB: anthonisen‘s criteria versus procalcitonin Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004 Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013 Procalcitonin and C reactive protein as markers of treatment failure in community-acquired pneumonia Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia Year: 2006 Can procalcitonin testing reduce antibiotic prescribing for respiratory infections? Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia Year: 2006 Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study Source: Eur Respir J 2009; 34: 1364-1375 Year: 2009 Which is the most effective inflammatory marker in the diagnosis, severity and treatment follow-up of patients with pneumonia? Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators Source: Eur Respir J 2007; 30: 556-573 Year: 2007 Are antimicrobials still the future of respiratory infection therapy? Source: Virtual Congress 2021 – Emerging data for the management of respiratory tract infections Year: 2021 May the value of FEV1 be helpful in the choice of the antibiotic therapy in acute exacerbation of COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001 Biomarkers of early diagnosis and therapeutic response in ventilator-associated pneumonia Source: Annual Congress 2011 - Molecular biomarkers at the bedside of critically ill patients Year: 2011 Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009 Procalcitonin has wider applicability in community-acquired pneumonia than other biomarkers Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018